Trevi Therapeutics, Inc. (TRVI) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $13.18: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 4.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 1.80; Below-average business quality.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.... Read more
Sell if holding. Engine safety override at $13.18: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 4.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 1.80; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.3/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Trevi Therapeutics, Inc.
Latest news
- Needham Reiterates Buy on Trevi Therapeutics, Maintains $23 Price Target — benzinga May 20, 2026 positive
- HC Wainwright & Co. Reiterates Buy on Trevi Therapeutics, Maintains $21 Price Target — benzinga May 6, 2026 positive
- Needham Maintains Buy on Trevi Therapeutics, Lowers Price Target to $23 — benzinga May 6, 2026 neutral
- Trevi Therapeutics Q1 2026 Earnings Call Transcript — benzinga May 5, 2026 neutral
- Trevi Therapeutics Q1 EPS $(0.09) Misses $(0.07) Estimate — benzinga May 5, 2026 negative
Generated 2026-05-20T21:56:22Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $13.18: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 4.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 1.80; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $12.72. Score 5.3/10, moderate confidence.
Take-profit target: $20.41 (+54.2% upside). Prior stop was $12.72. Stop-loss: $12.72.
Quality below floor (1.5 < 4.0).
Trevi Therapeutics, Inc. trades at a P/E of N/A (forward -25.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
18 analysts cover TRVI with a consensus score of 4.3/5. Average price target: $23.
What does Trevi Therapeutics, Inc. do?Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational...
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.